Genetics and prognostication in splenic marginal zone lymphoma: Revelations from deep sequencing

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4174-4183

  Parry, Marina ^a   Rose Zerilli, Matthew J J ^a   Ljungström, Viktor ^b   Gibson, Jane ^c   Wang, Jun ^d   Walewska, Renata ^e   Parker, Helen ^a   Parker, Anton ^e   Davis, Zadie ^e   Gardiner, Anne ^e   McIver Brown, Neil ^e   Kalpadakis, Christina ^f   Xochelli, Aliki ^g   Anagnostopoulos, Achilles ^h   Fazi, Claudia ⁱ   De Castro, David Gonzalez ^j   Dearden, Claire ^j   Pratt, Guy ^k,l   Rosenquist, Richard ^b   Ashton Key, Margaret ^a   Forconi, Francesco ^a   Collins, Andrew ^a   Ghia, Paolo ⁱ   Matutes, Estella ^m   Pangalis, Gerassimos ⁿ   Stamatopoulos, Kostas ^g,h   Oscier, David ^a,e   Strefford, Jonathan C ^a   more..

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^e ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^f UNIVERSITY OF CRETE   (Greece)

^g INFORMATION TECHNOLOGIES INSTITUTE   (Greece)

^h G PAPANICOLAOU HOSPITAL   (Greece)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^k UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^l UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^m HOSPITAL CLÍNIC   (Spain)

ⁿ ATHENS MEDICAL CENTER   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; DNA; IMMUNOGLOBULIN HEAVY CHAIN; KRUPPEL LIKE FACTOR 2; MIXED LINEAGE LEUKEMIA 2 PROTEIN; MIXED LINEAGE LEUKEMIA PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; NOTCH2 RECEPTOR; PROTEIN P53; UNCLASSIFIED DRUG; ARID1A PROTEIN, HUMAN; DNA BINDING PROTEIN; GENETIC MARKER; KLF2 PROTEIN, HUMAN; KRUPPEL LIKE FACTOR; MLL2 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; NOTCH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; SIGNAL PEPTIDE; TNFAIP3 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA INDUCED PROTEIN 3; TUMOR PROTEIN;

ADULT; AGED; ARID1A GENE; ARTICLE; CANCER GENETICS; CANCER PROGNOSIS; CHROMOSOME 7Q; CHROMOSOME DELETION; COHORT ANALYSIS; GENE; GENETIC ASSOCIATION; GERMLINE MUTATION; HUMAN; IMMUNOGENETICS; IMMUNOGLOBULIN HEAVY VARIABLE GENE; KLF2 GENE; MAJOR CLINICAL STUDY; MLL2 GENE; MUTATION RATE; MUTATIONAL ANALYSIS; MYD88 GENE; NOTCH2 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SOMATIC MUTATION; SPLENIC MARGINAL ZONE LYMPHOMA; SURVIVAL TIME; TIME TO TREATMENT; TNFAIP3 GENE; TP53 GENE; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC MARKER; GENETICS; HIGH THROUGHPUT SEQUENCING; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; RISK FACTOR; SPLENIC NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; DNA MUTATIONAL ANALYSIS; DNA-BINDING PROTEINS; FEMALE; GENETIC MARKERS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; LYMPHOMA, B-CELL, MARGINAL ZONE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROGNOSIS; RECEPTOR, NOTCH2; RISK FACTORS; SPLENIC NEOPLASMS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR ALPHA-INDUCED PROTEIN 3; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84942742967     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2759     Document Type: Article

References (40)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: World Health Organization; 2008.
2. Bikos V, Darzentas N, Hadzidimitriou A, Davis Z, Hockley S, Traverse- Glehen A, et al. Over 30% of patients with splenic marginal zone lymphoma express the same immunoglobulin heavy variable gene: ontogenetic implications. Leukemia 2012;26:1638-46.
3. SalidoM, Bar-o C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et al. Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. Blood 2010;116:1479-88.
4. Kalpadakis C, Pangalis GA, Angelopoulou MK, Sachanas S, Kontopidou FN, Yiakoumis X, et al. Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy. Oncologist 2013;18:190-7.
5. Lenglet J, Traullé C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S, et al. Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 2014;55:1854-60.
6. Montalbán C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado- Vasco P, Iannitto E, et al. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases. Br J Haematol 2013;159: 164-71.
7. Montalban C, Abraira V, Arcaini L, Domingo-Domenech E, Guisado-Vasco P, Iannitto E, et al. Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use. Leuk Lymphoma 2014;55:929-31.
8. Arcaini L, Lazzarino M, Colombo N, Burcheri S, Boveri E, Paulli M, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006;107:4643-9.
9. Algara P, Mateo MS, Sanchez-Beato M, Mollejo M, Navas IC, Romero L, et al. Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 2002;99:1299-304.
10. Gruszka-Westwood AM, Hamoudi RA, Matutes E, Tuset E, Catovsky D. p53 abnormalities in splenic lymphoma with villous lymphocytes. Blood 2001;97:3552-8.
11. Fresquet V, Robles EF, Parker A, Martinez-Useros J, Mena M, Malumbres R, et al. High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal- zone lymphoma. Br J Haematol 2012;158:712-26.
12. Hockley SL, Else M, Morilla A, Wotherspoon A, Dearden C, Catovsky D, et al. The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma. Br J Haematol 2012;158:347-54.
13. Rinaldi A, Mian M, Chigrinova E, Arcaini L, Bhagat G, Novak U, et al. Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood 2011;117:1595-604.
14. Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med 2012;209:1537-51.
15. Kiel MJ, Velusamy T, Betz BL, Zhao L, Weigelin HG, Chiang MY, et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. J Exp Med 2012;209: 1553-65.
16. Martínez N, Almaraz C, Vaqu-e JP, Varela I, Derdak S, Beltran S, et al. Wholeexome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. Leukemia 2014; 28:1334-40.
17. Parry M, Rose-Zerilli MJ, Gibson J, Ennis S, Walewska R, Forster J, et al. Whole exome sequencing identifies novel recurrently mutated genes in patients with splenic marginal zone lymphoma. PLoS One 2013;8: e83244.
18. Matutes E, Oscier D, Montalban C, Berger F, Callet-Bauchu E, Dogan A, et al. Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria. Leukemia 2008;22:487-95.
19. Xochelli A, Kalpadakis C, Gardiner A, Baliakas P, Vassilakopoulos TP, Mould S, et al. Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal zone origin: is this a distinct entity? Blood 2014;123:199-206.
20. Rossi D, Deaglio S, Dominguez-Sola D, Rasi S, Vaisitti T, AgostinelliC, et al. Alteration of BIRC3 and multiple other NF-kB pathway genes in splenic marginal zone lymphoma. Blood 2011;118:4930-4.
21. Novak U, Rinaldi A, Kwee I, Nandula SV, Rancoita PM, Compagno M, et al. The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. Blood 2009;113:4918-21.
22. Piva R, Deaglio S, Fam-a R, Buonincontri R, Scarf-o I, Bruscaggin A, et al. The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. Leukemia 2015;29:503-7.
23. Dees ND, Zhang Q, Kandoth C, Wendl MC, Schierding W, Koboldt DC, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res 2012;22:1589-98.
24. Carter SL, Cibulskis K, Helman E, McKenna A, Shen H, Zack T, et al. Absolute quantification of somatic DNA alterations in human cancer. Nat Biotech 2012;30:413-21.
25. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011; 470:115-9.
26. Honma K, Tsuzuki S, Nakagawa M, Tagawa H, Nakamura S, Morishima Y, et al. TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas. Blood 2009;114:2467-75.
27. Okosun J, Bödör C, Wang J, Araf S, Yang CY, Pan C, et al. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 2014;46:176-81.
28. Pasqualucci L, Dominguez-Sola D, Chiarenza A, Fabbri G, Grunn A, Trifonov V, et al. Inactivating mutations of acetyltransferase genes in Bcell lymphoma. Nature 2011;471:189-95.
29. Pearson R, Fleetwood J, Eaton S, Crossley M, Bao S. Kruppel-like transcription factors: A functional family. Int J Biochem Cell Biol 2008; 40:1996-2001.
30. Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. Leukemia. 2014 Nov 27. [Epub ahead of print].
31. Hart GT, Wang X, Hogquist KA, Jameson SC. Krüppel-like factor 2 (KLF2) regulates B-cell reactivity, subset differentiation, and trafficking molecule expression. Proc Natl Acad Sci U S A 2011;108: 716-21.
32. Hoek KL, Gordy LE, Collins PL, Parekh VV, Aune TM, Joyce S, et al. Follicular B cell trafficking within the spleen actively restricts humoral immune responses. Immunity 2010;33:254-65.
33. Hart GT, Peery SL, Hamilton SE, Jameson SC. Cutting edge: Kru-ppel-like factor 2 is required for phenotypic maintenance but not development of B1 B cells. J Immunol 2012;189:3293-7.
34. Strefford JC, Sutton LA, Baliakas P, Agathangelidis A, Mal-cíková J, Plevova K, et al. Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. Leukemia 2013;27:2196-9.
35. Saito T, Chiba S, IchikawaM, Kunisato A, Asai T, Shimizu K, et al. Notch2 is preferentially expressed in mature B cells and indispensable for marginal zone B lineage development. Immunity 2003;18:675-85.
36. Troussard X, Valensi F, Duchayne E, Garand R, Felman P, Tulliez M, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Groupe Francais d'H-ematologie Cellulaire (GFHC). Br J Haematol 1996;93:731-6.
37. Parry-Jones N, Matutes E, Gruszka-Westwood AM, Swansbury GJ, Wotherspoon AC, Catovsky D. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients. Br J Haematol 2003;120: 759-64.
38. Algrin C, Brisou G, Beldjord K, Mounier N, Berger F, Baseggio L, et al. Prognostic impact of somaticNOTCH2 mutation in splenic marginal zone lymphoma blood. 2013 Annual Meeting Abstracts. Blood 2013;122:4247.
39. Fabbri G, Khiabanian H, Holmes AB, Wang J, Messina M, Mullighan CG, et al. Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome. J Exp Med 2013;210:2273-88.
40. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 2013;152:714-26.